Pro-Dex Q3 EPS $0.19 Misses $0.35 Estimate, Sales $14.29M Beat $13.20M Estimate

5/2/24 4:06:02 PM ET

Medical/Dental Instruments

Health Care

Get the next $PDEX alert in real time by email

Pro-Dex (NASDAQ:PDEX) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.35 by 45.71 percent. This is a 47.22 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $14.29 million which beat the analyst consensus estimate of $13.20 million by 8.28 percent. This is a 9.28 percent increase over sales of $13.08 million the same period last year.

Get the next $PDEX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PDEX

Date	Price Target	Rating	Analyst

More analyst ratings

$PDEX
Press Releases

Fastest customizable press release news feed in the world

PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results
IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene
10/31/24 4:00:00 PM ET
$PDEX
Medical/Dental Instruments
Health Care
Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results
IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $
9/5/24 4:00:00 PM ET
$PDEX
Medical/Dental Instruments
Health Care
Pro-Dex, Inc. Announces Fiscal 2024 Third Quarter And Nine-Month Results
IRVINE, CA / ACCESSWIRE / May 2, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2024 with the Securities and Exchange Commission today.Quarter Ended March 31, 2024Net sales for the three months ended March 31, 2024, increased $1.2 million, or 9%, to $14.3 million from $13.1 million for the three months ended March 31, 2023, due primarily to an increase in medical device product revenue of $2.8 million offset by a decrease in non-recurring engineering and repair revenue of $736,000 and $635,000 respectively.Gross profit for
5/2/24 4:00:00 PM ET
$PDEX
Medical/Dental Instruments
Health Care

$PDEX
Financials

Live finance-specific insights

PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results
IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene
10/31/24 4:00:00 PM ET
$PDEX
Medical/Dental Instruments
Health Care
Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results
IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $
9/5/24 4:00:00 PM ET
$PDEX
Medical/Dental Instruments
Health Care
Pro-Dex, Inc. Announces Fiscal 2024 First Quarter Results
IRVINE, CA / ACCESSWIRE / November 2, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 first quarter ended September 30, 2023. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2024 with the Securities and Exchange Commission today.Net sales for the three months ended September 30, 2023, increased $851,000, or 8%, to $11.9 million from $11.1 million for the three months ended September 30, 2022. The increase is driven primarily by $1.8 million in increased repairs of the surgical handpiece we sell to our largest customer offset primarily by a decrease of $0.7 million in sales of our NRE & proto-type offerings
11/2/23 4:00:00 PM ET
$PDEX
Medical/Dental Instruments
Health Care

$PDEX
Market Insights

Live Market Insights

Pro-Dex Q3 EPS $0.19 Misses $0.35 Estimate, Sales $14.29M Beat $13.20M Estimate
Pro-Dex (NASDAQ:PDEX) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.35 by 45.71 percent. This is a 47.22 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $14.29 million which beat the analyst consensus estimate of $13.20 million by 8.28 percent. This is a 9.28 percent increase over sales of $13.08 million the same period last year.
5/2/24 4:06:02 PM ET
$PDEX
Medical/Dental Instruments
Health Care
Pro-Dex Q2 EPS $0.14, Sales $12.59M Beat $11.50M Estimate
Pro-Dex (NASDAQ:PDEX) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.35 by 60 percent. This is a 41.67 percent decrease over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $12.59 million which beat the analyst consensus estimate of $11.50 million by 9.46 percent. This is a 11.58 percent increase over sales of $11.28 million the same period last year.
2/8/24 4:58:14 PM ET
$PDEX
Medical/Dental Instruments
Health Care
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Xilio Therapeutics (NASDAQ:XLO) shares rose 10.5% to $0.66 during Thursday's after-market session. The market value of their outstanding shares is at $18.2 million. Sensus Healthcare (NASDAQ:SRTS) stock increased by 9.58% to $4.0. The company's market cap stands at $65.5 million. The company's, Q4 earnings came out today. Corvus Pharma (NASDAQ:CRVS) stock moved upwards by 8.49% to $2.17. The market value of their outstanding shares is at $106.4 million. SenesTech (NASDAQ:SNES) shares moved upwards by 6.86% to $1.09. Coeptis Therapeutics (NASDAQ:COEP) stock rose 6.2% to $0.51. The company's market cap stands at $17.3 million. Bright Green (NASDAQ:BGXX) shares moved upwards by 4.
2/8/24 4:31:10 PM ET
$BGXX
$BTAI
$COEP
$CRVS
Medicinal Chemicals and Botanical Products
Health Care
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)

Pro-Dex Q3 EPS $0.19 Misses $0.35 Estimate, Sales $14.29M Beat $13.20M Estimate

Chat with this insight

Recent Analyst Ratings for
$PDEX

$PDEX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by Pro-Dex Inc.

SEC Form SC 13D/A filed

$PDEX
Press Releases

Fastest customizable press release news feed in the world

PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

Pro-Dex, Inc. Announces Fiscal 2024 Third Quarter And Nine-Month Results

$PDEX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Charlton Alisha sold $40,020 worth of shares (1,000 units at $40.02), decreasing direct ownership by 6% to 15,339 units (SEC Form 4)

Director Domingo Angelita Rebamontan was granted 40 shares, increasing direct ownership by 0.32% to 12,437 units (SEC Form 4)

Director Domingo Angelita Rebamontan was granted 6,800 shares and covered exercise/tax liability with 2,594 shares, increasing direct ownership by 51% to 12,397 units (SEC Form 4)

$PDEX
Financials

Live finance-specific insights

PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

Pro-Dex, Inc. Announces Fiscal 2024 First Quarter Results

$PDEX
SEC Filings

Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Pro-Dex Inc.

Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

$PDEX
Market Insights

Live Market Insights